Novel behavioural characteristics of the APPSwe/PS1ΔE9 transgenic mouse model of Alzheimer's disease

Behavioural Brain Research

Volumn 245, Issue , 2013, Pages 120-127

  Cheng, David ^a,b   Logge, Warren ^a,c   Low, Jac Kee ^a,c   Garner, Brett ^d   Karl, Tim ^a,b,c  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Alzheimer's disease; Behaviour; Cheeseboard; Sensorimotor gating; Social recognition memory; Transgenic APPSwe PS1 E9 mice

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONDITIONING; CONTROLLED STUDY; DISEASE MODEL; FEAR; HYPERACTIVITY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MENTAL TASK; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENSORY GATING; SOCIAL COGNITION; SPATIAL LEARNING; TRANSGENIC MOUSE;

ACOUSTIC STIMULATION; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; COGNITION; CONDITIONING (PSYCHOLOGY); DARKNESS; FEAR; HUMANS; LIGHT; MEMORY; MICE; MICE, TRANSGENIC; PRESENILIN-1; SENSORY GATING; SMELL; SOCIAL BEHAVIOR; STARTLE REACTION;

EID: 84875244381     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.02.008     Document Type: Article

References (63)

1. Gotz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nature Reviews Neuroscience 2008, 9:532-544.
2. Karl T., Cheng D., Garner B., Arnold J.C. The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opinion on Therapeutic Targets 2012, 16:407-420.
3. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
4. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Human Molecular Genetics 2004, 13:159-170.
5. Jankowsky J.L., Slunt H.H., Gonzales V., Jenkins N.A., Copeland N.G., Borchelt D.R. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiology of Aging 2004, 25:885-892.
6. Swe and PS1 double transgenic mice. Neurobiology of Disease 2003, 14:318-327.
7. Swe/PS1dE9 mice. Neurobiology of Aging 2008, 29:368-378.
8. Swe/PS1dE9 transgenic mice. Neurobiology of Disease 2010, 38:27-35.
9. Cao D., Lu H., Lewis T.L., Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. Journal of Biological Chemistry 2007, 282:36275-36282.
10. Swe+PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes, Brain and Behavior 2007, 6:54-65.
11. Swe/PS1dE9 mice. Neurobiology of Disease 2009, 33:482-498.
12. Swe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiology of Disease 2005, 18:602-617.
13. Swe/PS1dE9 mouse model of Alzheimer's disease. Behavioural Brain Research 2011, 222:342-350.
14. Swe+PS1/DeltaE9 mice. Neuroscience Letters 2004, 369:156-161.
15. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:11784-11789.
16. Swe/PS1dE9 mice with differential effects on brain Abeta levels. Neurobiology of Disease 2010, 40:340-347.
17. Swe/PS1dE9 mouse model of Alzheimer's disease. Behavioural Brain Research 2009, 201:120-127.
18. Pistell P.J., Zhu M., Ingram D.K. Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Neuroscience 2008, 152:594-600.
19. Karl T., Bhatia S., Cheng D., Kim W.S., Garner B. Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. Behavioural Brain Research 2012, 228:392-397.
20. Faizi M., Bader P.L., Saw N., Nguyen T.V., Beraki S., Wyss-Coray T., et al. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain and Behavior 2012, 2:142-154.
21. Pillay N.S., Kellaway L.A., Kotwal G.J. Early detection of memory deficits and memory improvement with vaccinia virus complement control protein in an Alzheimer's disease model. Behavioural Brain Research 2008, 192:173-177.
22. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
23. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular Engineering 2001, 17:157-165.
24. Karl T., Pabst R., von Horsten S. Behavioral phenotyping of mice in pharmacological and toxicological research. Experimental and Toxicologic Pathology 2003, 55:69-83.
25. Crawley J.N., Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Hormones and Behavior 1997, 31:197-211.
26. Karl T., Duffy L., Scimone A., Harvey R.P., Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes, Brain and Behavior 2007, 6:677-687.
27. Montgomery K.C. The relation between fear induced by novel stimulation and exploratory behavior. Journal of Comparative and Physiological Psychology 1955, 48:254-260.
28. Montgomery K.C., Monkman J.A. The relation between fear and exploratory behavior. Journal of Comparative and Physiological Psychology 1955, 48:132-136.
29. Karl T., Duffy L., Herzog H. Behavioural profile of a new mouse model for NPY deficiency. European Journal of Neuroscience 2008, 28:173-180.
30. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., et al. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes, Brain and Behavior 2004, 3:287-302.
31. Moy S.S., Nadler J.J., Young N.B., Nonneman R.J., Segall S.K., Andrade G.M., et al. Social approach and repetitive behavior in eleven inbred mouse strains. Behavioural Brain Research 2008, 191:118-129.
32. Chesworth R., Downey L., Logge W., Killcross S., Karl T. Cognition in female transmembrane domain neuregulin 1 mutant mice. Behavioural Brain Research 2012, 226:218-223.
33. Duffy L., Cappas E., Lai D., Boucher A.A., Karl T. Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 2010, 170:800-807.
34. Logge W., Cheng D., Chesworth R., Bhatia S., Garner B., Kim W.S., et al. Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases. PLoS ONE 2012, 7:e45959.
35. Wang H., He J., Zhang R., Zhu S., Wang J., Kong L., et al. Sensorimotor gating and memory deficits in an APP/PS1 double transgenic mouse model of Alzheimer's disease. Behavioural Brain Research 2012, 233:237-243.
36. van den Buuse M., Wischhof L., Lee R.X., Martin S., Karl T. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. International Journal of Neuropsychopharmacology 2009, 12:1383-1393.
37. Karl T., Burne T.H., Van den Buuse M., Chesworth R. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit. Behavioural Brain Research 2011, 223:336-341.
38. Liebenauer L.L., Slotnick B.M. Social organization and aggression in a group of olfactory bulbectomized male mice. Physiology and Behavior 1996, 60:403-409.
39. Chung J.A., Cummings J.L. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurologic Clinics 2000, 18:829-846.
40. Melnikova T., Savonenko A., Wang Q., Liang X., Hand T., Wu L., et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006, 141:1149-1162.
41. Echávarri C., Burgmans S., Uylings H., Cuesta M.J., Peralta V., Kamphorst W., et al. Neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. Journal of Alzheimer's Disease 2013, 33(3):715-721.
42. Mesholam R.I., Moberg P.J., Mahr R.N., Doty R.L. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases. Archives of Neurology 1998, 55:84-90.
43. Wesson D.W., Borkowski A.H., Landreth G.E., Nixon R.A., Levy E., Wilson D.A. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's beta-amyloidosis mouse model. Journal of Neuroscience 2011, 31:15962-15971.
44. Rey N.L., Jardanhazi-Kurutz D., Terwel D., Kummer M.P., Jourdan F., Didier A., et al. Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice. Neurobiology of Aging 2012, 33:426 e1-4311e.
45. Reisberg B., Ferris S.H., de Leon M.J., Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. The American Journal of Psychiatry 1982, 139:1136-1139.
46. Brown M.W., Aggleton J.P. Recognition memory: what are the roles of the perirhinal cortex and hippocampus. Nature Reviews Neuroscience 2001, 2:51-61.
47. Laakso M.P., Hallikainen M., Hanninen T., Partanen K., Soininen H. Diagnosis of Alzheimer's disease: MRI of the hippocampus vs delayed recall. Neuropsychologia 2000, 38:579-584.
48. Poulin S.P., Dautoff R., Morris J.C., Barrett L.F., Dickerson B.C. Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Research 2011, 194:7-13.
49. Swe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease. Behavioural Brain Research 2011, 222:89-97.
50. Donkin J.J., Stukas S., Hirsch-Reinshagen V., Namjoshi D., Wilkinson A., May S., et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. Journal of Biological Chemistry 2010, 285:34144-34154.
51. Jardanhazi-Kurutz D., Kummer M.P., Terwel D., Vogel K., Dyrks T., Thiele A., et al. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochemistry International 2010, 57:375-382.
52. Gimbel D.A., Nygaard H.B., Coffey E.E., Gunther E.C., Lauren J., Gimbel Z.A., et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. Journal of Neuroscience 2010, 30:6367-6374.
53. Yoshiike Y., Kimura T., Yamashita S., Furudate H., Mizoroki T., Murayama M., et al. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 2008, 3:e3029.
54. Llano Lopez L., Hauser J., Feldon J., Gargiulo P.A., Yee B.K. Evaluating spatial memory function in mice: a within-subjects comparison between the water maze test and its adaptation to dry land. Behavioural Brain Research 2010, 209:85-92.
55. Gerlai R. Behavioral tests of hippocampal function: simple paradigms complex problems. Behavioural Brain Research 2001, 125:269-277.
56. Iivonen H., Nurminen L., Harri M., Tanila H., Puolivali J. Hypothermia in mice tested in Morris water maze. Behavioural Brain Research 2003, 141:207-213.
57. Mizunoya W., Oyaizu S., Hirayama A., Fushiki T. Effects of physical fatigue in mice on learning performance in a water maze. Bioscience, Biotechnology, and Biochemistry 2004, 68:827-834.
58. Wolfer D.P., Stagljar-Bozicevic M., Errington M.L., Lipp H.P. Spatial memory and learning in transgenic mice: fact or artifact?. News in Physiological Science 1998, 13:118-123.
59. Swe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test. Biogerontology 2008, 9:405-420.
60. Jessen F., Kucharski C., Fries T., Papassotiropoulos A., Hoenig K., Maier W., et al. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. The American Journal of Psychiatry 2001, 158:1319-1321.
61. Ewers M., Morgan D.G., Gordon M.N., Woodruff-Pak D.S. Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiology of Aging 2006, 27:1118-1128.
62. Gogos A., van den Buuse M., Rossell S. Gender differences in prepulse inhibition (PPI) in bipolar disorder: men have reduced PPI, women have increased PPI. International Journal of Neuropsychopharmacology 2009, 12:1249-1259.
63. Ison J.R., Allen P.D. Pre- but not post-menopausal female CBA/CaJ mice show less prepulse inhibition than male mice of the same age. Behavioural Brain Research 2007, 185:76-81.